KYNAMRO Drug Patent Profile

Which patents cover Kynamro, and what generic alternatives are available?

Kynamro is a drug marketed by Kastle Theraps Llc and is included in one NDA. There is one patent protecting this drug.

This drug has forty-five patent family members in eleven countries.

The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Kynamro

Kynamro was eligible for patent challenges on January 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 29, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for KYNAMRO

International Patents:	45
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	396
Drug Prices:	Drug price information for KYNAMRO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for KYNAMRO
What excipients (inactive ingredients) are in KYNAMRO?	KYNAMRO excipients list
DailyMed Link:	KYNAMRO at DailyMed

See drug prices for KYNAMRO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KYNAMRO

NDA:

203568

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for KYNAMRO

KYNAMRO is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013		DISCN	Yes	No				Y

Expired US Patents for KYNAMRO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013
Kastle Theraps Llc	KYNAMRO	mipomersen sodium	SOLUTION;SUBCUTANEOUS	203568-001	Jan 29, 2013

EU/EMA Drug Approvals for KYNAMRO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Genzyme Europe BV	Kynamro	mipomersen sodium	EMEA/H/C/002429treatment of cholesterol and hypercholesterolaemia	Refused	no	no	no		2013-05-29

International Patents for KYNAMRO

See the table below for patents covering KYNAMRO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	154947
Austria	159025
Austria	160353

KYNAMRO (mipomersen) Market Dynamics and Financial Trajectory: Exclusivity, Access, Competition, and Revenue Decline

Last updated: June 26, 2026

Kynamro (mipomersen) has exited the active revenue growth phase. Its commercial trajectory has been constrained by restricted prescribing access in major markets, safety and monitoring burdens tied to hepatic fat accumulation and injection site/systemic tolerability issues, and persistent competitive substitution from LDL-C lowering platforms with broader outcome evidence. In the US, Kynamro’s sales base has also been structurally limited by the lack of sustained new indication expansion and by the availability of alternative therapies that reached standard-of-care adoption before mipomersen could regain momentum.

Why did KYNAMRO sales peak and then decline?

Kynamro’s early market uptake depended on a defined patient niche: individuals with heterozygous or homozygous familial hypercholesterolemia (HeFH and HoFH) and other severe, refractory hypercholesterolemia phenotypes with inadequate response or intolerance to existing LDL-lowering regimens. Demand strengthened when:

• The unmet need for additional LDL-C reduction was high in genetically confirmed or treatment-refractory populations.
• Physicians had limited access to later-generation therapies that now dominate severe hypercholesterolemia treatment algorithms.
• Pricing and access were tolerable relative to the high burden of progressive atherosclerotic risk in poorly controlled patients.

Sales then moved into decline because the practical and clinical barriers outweighed incremental LDL-C lowering benefits.

What clinical and safety factors constrained adoption?

Kynamro (mipomersen) is an antisense oligonucleotide targeting apolipoprotein B-100 production. Key adoption headwinds were:

• Hepatic fat accumulation and elevated liver enzymes, driving frequent monitoring requirements and dosing interruptions.
• Injection-site reactions and systemic tolerability issues typical of chronic subcutaneous biologic-like therapies.
• A lack of broad, hard-outcome data compared with therapies that improved cardiovascular endpoints, which reduced willingness to maintain long-term treatment when safer and more effective standard options became available.

How did standard-of-care substitution shift the market?

The most consequential market shift was the arrival and scaling of agents with more favorable benefit-risk profiles and stronger outcomes data:

• PCSK9 inhibitors (subcutaneous, less intensive monitoring than mipomersen, strong LDL-C reductions, and cardiovascular outcomes evidence)
• Modern intensive statin/ezetimibe combinations and guideline-driven escalation pathways
• In some subsets, emerging LDL-C pathway agents reduced the incremental need for mipomersen

As PCSK9 inhibitors and optimized oral regimens became routine, mipomersen’s addressable population compressed and stayed compressed.

What patents protect KYNAMRO and how does that affect generic competition?

Kynamro is a small-molecule-free, sequence-defined antisense oligonucleotide product. IP protection in this category is primarily layered through composition-of-matter, oligonucleotide sequence variants, delivery/chemistry, and method-of-use claims. The result is that “generic” entry is not a straightforward pathway and typically requires non-infringing workarounds or a challenge to specific claims.

Is there a “generic KYNAMRO” product?

No marketed generic or direct-to-reference generic equivalent has become established in the major markets in the way that small-molecule generics do. In practice, any competitive entry would likely be pursued as:

• A biosimilar-like development strategy does not map cleanly because antisense oligonucleotides are not regulated under the biologics pathway.
• A non-infringing alternative oligonucleotide sequence or formulation strategy that clears chemistry/manufacturing/clinical requirements and avoids key patent claims.

How long do exclusivity and patent barriers typically extend for antisense oligos?

For antisense therapies, patent estates often run well beyond initial FDA approval dates due to continuation filings and claim scope across:

• Exact sequence and backbone chemistry
• Conjugation or target-binding region modifications
• Manufacturing impurities and process claims
• Labeling and patient selection (method-of-use and indication claims)

This structure delays direct competition even after the first wave of market penetration.

What is the Orange Book status of KYNAMRO?

Kynamro is not a conventional small-molecule product with a typical ANDA-style “Orange Book to generic substitution” pathway in the way many statins are. Its competitive landscape historically depended more on patent litigation, access restrictions, and clinical adoption dynamics than on ANDA-driven market disruption.

Does Orange Book listing predict competitive entry for KYNAMRO?

Orange Book listings can indicate patent expiration timing, but for antisense oligonucleotides the primary determinants of entry are:

• Whether a competitor can design around sequence-specific claims
• Whether method-of-use claims restrict patient populations
• Whether formulation and manufacturing process claims are broad enough to block replication

Net effect: Orange Book status is less predictive of a swift generic launch and more predictive of whether competitors can clear patent barriers.

What FDA and REMS-style constraints matter for KYNAMRO commercialization?

Kynamro’s commercial trajectory is tightly linked to the practicalities of initiating and sustaining therapy with ongoing safety monitoring.

How do monitoring burdens affect treatment persistence?

Chronic therapy in high-risk lipid patients requires:

• Frequent liver-related monitoring
• Protocolized patient selection
• Treatment interruptions in response to lab abnormalities

These operational demands reduce the number of eligible patients and shorten average treatment persistence relative to lower-monitoring competitors.

How does risk management shape physician adoption?

Risk management requirements increase clinical workflow friction, which can limit:

• Prescriber willingness to initiate therapy
• Health system support for longitudinal follow-up
• Patient willingness to remain on treatment for months to years

This shifts demand from broader specialty adoption to narrow, referral-driven use.

How does KYNAMRO revenue compare with PCSK9 inhibitors and other LDL-lowering therapies?

Kynamro’s revenue scale has historically been small relative to PCSK9 inhibitors and large oral regimens due to:

• Narrow patient eligibility
• Monitoring and tolerability constraints
• Rapid substitution once PCSK9 inhibitors gained broad coverage
• Reduced urgency as LDL-C lowering improved across standard-of-care pathways

What competitive dynamics are most damaging to antisense niche drugs?

Antisense products face a recurring commercial pattern:

1. Initial niche adoption based on lack of alternatives
2. Rapid competitive pressure from less burdensome therapies that achieve similar or greater LDL-C reduction
3. Contracting in formularies and restrictive coverage policies once outcomes evidence accumulates for substitutes

Kynamro fits this pattern.

When does KYNAMRO lose exclusivity and what launch risks exist for competitors?

Without a complete, validated dataset of specific Kynamro listed patents and expiration dates for each jurisdiction, a definitive “loss of exclusivity” timeline cannot be stated with precision.

That said, the effective exclusion from mainstream markets has been driven less by headline expiration dates and more by:

• Layered claim coverage that requires careful design-around
• Clinical and access constraints that reduced the addressable population even while IP remained intact
• A competitive environment where substitutes achieved stronger guideline adoption

What generic entry risks exist for antisense oligonucleotides?

For competitors, the launch risks typically include:

• Patent infringement exposure on exact-sequence and target-binding claims
• Method-of-use claims limiting label-anchored prescribing
• Manufacturing validation risk tied to batch-to-batch impurity profiles
• Clinical risk from safety-related monitoring expectations

The net effect is that even if entry is legally possible, market uptake can remain constrained if payers and prescribers do not restart high-monitoring therapy pathways.

What patent litigation and settlements affected KYNAMRO’s competitive landscape?

Kynamro’s market development has been influenced by enforcement risk around antisense-specific claim sets and patient selection labeling. However, without a verified list of case captions, docket outcomes, and settlement terms, litigation-specific timing and settlement impacts cannot be accurately mapped to revenue changes.

What formulation and method-of-use protections matter for KYNAMRO?

For antisense oligonucleotides, protective coverage commonly extends to:

• The oligonucleotide sequence and its chemical backbone attributes
• Drug substance and drug product specifications tied to stability and purity
• Methods of using the therapy in targeted patient subsets (e.g., severe familial hypercholesterolemia, refractory LDL-C states, specific baseline lipid or genetic criteria)

These layers can limit substitution even when broad indications overlap.

What is the commercial trajectory of KYNAMRO by phase of life cycle?

Kynamro’s financial trajectory is best characterized in lifecycle terms:

• Launch and early uptake: concentrated in severe hypercholesterolemia referrals where clinicians sought additional LDL-C lowering beyond existing regimens.
• Peak then contraction: adoption slowed as clinical practice shifted toward newer LDL-lowering agents with broader outcomes adoption and less demanding monitoring.
• Sustained niche use: continued sales likely depended on remaining eligible patients and access through specialty channels, but the growth runway shrank.

Key Takeaways

• Kynamro’s market has been structurally niche due to safety monitoring burdens and injection/tolerability constraints.
• Adoption eroded as PCSK9 inhibitors and optimized lipid-lowering standard-of-care expanded, compressing the addressable severe hypercholesterolemia population that would choose mipomersen.
• Patent and regulatory barriers for antisense oligonucleotides reduce generic-like substitution risk but do not prevent revenue decline when clinical practice shifts.
• Competitive substitution, access dynamics, and treatment persistence constraints are the dominant drivers of the financial trajectory, not only exclusivity timing.

FAQs

1. Why did mipomersen face lower payer adoption than PCSK9 inhibitors?
2. Does mipomersen have cardiovascular outcomes evidence comparable to PCSK9 inhibitor trials?
3. What monitoring schedule is required for KYNAMRO liver-related safety?
4. How do patient selection criteria limit mipomersen eligible populations in practice?
5. Can competitors launch an antisense oligonucleotide LDL-C therapy without infringing KYNAMRO patents?

References

1. FDA Labeling and prescribing information for KYNAMRO (mipomersen) and associated safety information.
2. FDA/Drugs@FDA product records for KYNAMRO (mipomersen).
3. Orange Book patent listing framework and general guidance on exclusivity and patent barriers (US FDA Orange Book methodology).